206-838-5110 ext. 102 general@etubics.com

Press Releases

Etubics Adds Caskey, Paessler, Zeldis to Leadership Boards

SEATTLE – (July 20, 2015) - Etubics Corporation, a privately-held, clinical stage biotechnology company developing an immunotherapy vaccine platform, has added Dr. Thomas Caskey to its Board of Directors and Drs. / Jerome Zeldis, Slobodan Paessler to its Scientific...

Gerald L. Messerschmidt Joins Etubics as Chief Medical Officer

SEATTLE – (July 9, 2015) - Etubics Corporation, a privately-held, clinical stage biotechnology company developing an immunotherapy vaccine platform, announced today that it has retained Gerald L. Messerschmidt, MD, FACP as Chief Medical Officer. The company is...

Etubics Will Present Results of its Colorectal Cancer Phase 1 and 2 Immunotherapy Trial at the Annual American Society of Clinical Oncology Meeting In Chicago

Etubics Corporation, a clinical stage biotechnology company with a proprietary platform technology that delivers a long lasting “active” immune response against diseases, will present clinical data from its Phase 1/2 proof of concept clinical trials using an immunotherapeutic to treat patients

Categories

  • No categories

Archives

Media Contact:

Jen Hodson
NantWorks
562-397-3639
Press@NantHealth.com